Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
By: GlobeNewswire - 24 Apr 2024 | Back to overview list |
|
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the company’s therapeutic cancer vaccine candidate UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab as first-line treatment in unresectable or metastatic malignant melanoma. The trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and 156 patients were enrolled between June 2020 and July 2022. The poster presentation features key findings and analyses after a minimum 18-month follow-up of the patients in the trial. Presentation Details: Abstract Number: LBA9519 Late-Breaking Abstracts are under embargo and will be released at 7:00 AM (CT)/8:00 AM (ET) on the day of the presentation. ==ENDS== About Ultimovacs The Company is listed on the Euronext Oslo Stock Exchange (ULTI). For further information, please contact: Carlos de Sousa, CEO Anne Worsøe, Head of Investor Relations This stock exchange announcement was published by Anne Worsøe, Head of Investor Relations at Ultimovacs ASA, on April 24, 2024, at 16:15 CET. |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |